Roche OTC sales
This article was originally published in The Tan Sheet
Executive Summary
First quarter revenues were up 5% in local currencies to $328 mil., Swiss firm announces April 21. Excluding Chugai OTCs in Japan, sales were ahead 8% in local currencies, outpacing the market, Roche added. The increase was driven by solid growth in core markets Spain, the UK, Brazil and Turkey. A decision on the divestiture of the Consumer Health group is expected in the second half, the firm said. Roche could have a buyer for the business by early summer (1"The Tan Sheet" March 22, 2004, p. 7)...
You may also be interested in...
Roche Could Have Buyer For OTC Unit By Early Summer
Potential suitors for Roche's consumer health unit will lay out their strategy for the business next month as the divestiture process of the OTC division picks up speed
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.